Although there is agreement among studies performed by various investigators that ADIPOQ gene polymorphisms do influence the response to pioglitazone in T2DM patients, the results of individual studies are inconsistent [11], [12], [13]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.